189 related articles for article (PubMed ID: 25579888)
21. Prediction of NK Cell Licensing Level in Selection of Hematopoietic Stem Cell Donor, Initial Results.
Rogatko-Koroś M; Mika-Witkowska R; Bogunia-Kubik K; Wysoczańska B; Jaskuła E; Kościńska K; Nestorowicz K; Dziopa J; Szlendak U; Gwozdowicz S; Graczyk-Pol E; Lange A; Nowak J
Arch Immunol Ther Exp (Warsz); 2016 Dec; 64(Suppl 1):63-71. PubMed ID: 27933342
[TBL] [Abstract][Full Text] [Related]
22. Conventional versus reduced-intensity conditioning regimen for allogeneic stem cell transplantation in patients with hematological malignancies.
Valcárcel D; Martino R; Sureda A; Canals C; Altés A; Briones J; Sanz MA; Parody R; Constans M; Villela SL; Brunet S; Sierra J
Eur J Haematol; 2005 Feb; 74(2):144-51. PubMed ID: 15654906
[TBL] [Abstract][Full Text] [Related]
23. Lowering the alemtuzumab dose in reduced intensity conditioning allogeneic hematopoietic cell transplantation is associated with a favorable early intense natural killer cell recovery.
Gärtner F; Hieke S; Finke J; Bertz H
Cytotherapy; 2013 Oct; 15(10):1237-44. PubMed ID: 23993297
[TBL] [Abstract][Full Text] [Related]
24. Comparison of outcomes after two standards-of-care reduced-intensity conditioning regimens and two different graft sources for allogeneic stem cell transplantation in adults with hematologic diseases: a single-center analysis.
Le Bourgeois A; Mohr C; Guillaume T; Delaunay J; Malard F; Loirat M; Peterlin P; Blin N; Dubruille V; Mahe B; Gastinne T; Le Gouill S; Moreau P; Mohty M; Planche L; Lode L; Bene MC; Chevallier P
Biol Blood Marrow Transplant; 2013 Jun; 19(6):934-9. PubMed ID: 23523970
[TBL] [Abstract][Full Text] [Related]
25. Antithymocyte globulin in reduced-intensity conditioning regimen allows a high disease-free survival exempt of long-term chronic graft-versus-host disease.
Devillier R; Fürst S; El-Cheikh J; Castagna L; Harbi S; Granata A; Crocchiolo R; Oudin C; Mohty B; Bouabdallah R; Chabannon C; Stoppa AM; Charbonnier A; Broussais-Guillaumot F; Calmels B; Lemarie C; Rey J; Vey N; Blaise D
Biol Blood Marrow Transplant; 2014 Mar; 20(3):370-4. PubMed ID: 24315846
[TBL] [Abstract][Full Text] [Related]
26. Long-term outcome of HLA-haploidentical hematopoietic stem cell transplantation without in vitro T-cell depletion based on an FBCA conditioning regimen for hematologic malignancies.
Lin X; Lu ZG; Song CY; Huang YX; Guo KY; Deng L; Tu SF; He YZ; Xu JH; Long H; Wu BY
Bone Marrow Transplant; 2015 Aug; 50(8):1092-7. PubMed ID: 25961770
[TBL] [Abstract][Full Text] [Related]
27. Early Natural Killer Cell Reconstitution Predicts Overall Survival in T Cell-Replete Allogeneic Hematopoietic Stem Cell Transplantation.
Minculescu L; Marquart HV; Friis LS; Petersen SL; Schiødt I; Ryder LP; Andersen NS; Sengeloev H
Biol Blood Marrow Transplant; 2016 Dec; 22(12):2187-2193. PubMed ID: 27664326
[TBL] [Abstract][Full Text] [Related]
28. Donor KIR3DL1/3DS1 gene and recipient Bw4 KIR ligand as prognostic markers for outcome in unrelated hematopoietic stem cell transplantation.
Gagne K; Busson M; Bignon JD; Balère-Appert ML; Loiseau P; Dormoy A; Dubois V; Perrier P; Jollet I; Bois M; Masson D; Moine A; Absi L; Blaise D; Charron D; Raffoux C;
Biol Blood Marrow Transplant; 2009 Nov; 15(11):1366-75. PubMed ID: 19822295
[TBL] [Abstract][Full Text] [Related]
29. Donor-Recipient Matching for KIR Genotypes Reduces Chronic GVHD and Missing Inhibitory KIR Ligands Protect against Relapse after Myeloablative, HLA Matched Hematopoietic Cell Transplantation.
Faridi RM; Kemp TJ; Dharmani-Khan P; Lewis V; Tripathi G; Rajalingam R; Daly A; Berka N; Storek J; Masood Khan F
PLoS One; 2016; 11(6):e0158242. PubMed ID: 27341514
[TBL] [Abstract][Full Text] [Related]
30. The role of missing killer cell immunoglobulin-like receptor ligands in T cell replete peripheral blood stem cell transplantation from HLA-identical siblings.
Clausen J; Kircher B; Auberger J; Schumacher P; Ulmer H; Hetzenauer G; Wolf D; Gastl G; Nachbaur D
Biol Blood Marrow Transplant; 2010 Feb; 16(2):273-80. PubMed ID: 19857587
[TBL] [Abstract][Full Text] [Related]
31. Rapid immune reconstitution after a reduced-intensity conditioning regimen and a CD3-depleted haploidentical stem cell graft for paediatric refractory haematological malignancies.
Chen X; Hale GA; Barfield R; Benaim E; Leung WH; Knowles J; Horwitz EM; Woodard P; Kasow K; Yusuf U; Behm FG; Hayden RT; Shurtleff SA; Turner V; Srivastava DK; Handgretinger R
Br J Haematol; 2006 Nov; 135(4):524-32. PubMed ID: 17010105
[TBL] [Abstract][Full Text] [Related]
32. Immune reconstitution after haploidentical hematopoietic stem cell transplantation.
Chang YJ; Zhao XY; Huang XJ
Biol Blood Marrow Transplant; 2014 Apr; 20(4):440-9. PubMed ID: 24315844
[TBL] [Abstract][Full Text] [Related]
33. Alloreactivity as therapeutic principle in the treatment of hematologic malignancies. Studies of clinical and immunologic aspects of allogeneic hematopoietic cell transplantation with nonmyeloablative conditioning.
Petersen SL
Dan Med Bull; 2007 May; 54(2):112-39. PubMed ID: 17521527
[TBL] [Abstract][Full Text] [Related]
34. Higher Dose of CD34
Zhao F; Shi Y; Chen X; Zhang R; Pang A; Zhai W; Yang D; He Y; Feng S; Zhang P; Jiang E; Han M
Transplant Cell Ther; 2022 Sep; 28(9):589.e1-589.e10. PubMed ID: 35714907
[TBL] [Abstract][Full Text] [Related]
35. Prognostic impact of immune status and hematopoietic recovery before and after fludarabine, IV busulfan, and antithymocyte globulins (FB2 regimen) reduced-intensity conditioning regimen (RIC) allogeneic stem cell transplantation (allo-SCT).
Le Bourgeois A; Lestang E; Guillaume T; Delaunay J; Ayari S; Blin N; Clavert A; Tessoulin B; Dubruille V; Mahe B; Roland V; Gastinne T; Le Gouill S; Moreau P; Mohty M; Planche L; Chevallier P
Eur J Haematol; 2013 Mar; 90(3):177-86. PubMed ID: 23301689
[TBL] [Abstract][Full Text] [Related]
36. Phase II prospective study of treosulfan-based reduced-intensity conditioning in allogeneic HSCT for hematological malignancies from 10/10 HLA-identical unrelated donor.
Michallet M; Sobh M; Milpied N; Bay JO; Fürst S; Harousseau JL; Mohty M; Nicolini FE; Labussière H; Tedone N; Morisset S; Vigouroux S; Baumgart J; Tabrizi R; Blaise D
Ann Hematol; 2012 Aug; 91(8):1289-97. PubMed ID: 22362122
[TBL] [Abstract][Full Text] [Related]
37. Assessment of immune reconstitution status in recipients of a successful hematopoietic stem cell transplant from peripheral blood after reduced intensity conditioning.
Jaime-Pérez JC; Villarreal-Villarreal CD; Méndez-Ramírez N; Vázquez-Garza E; Salazar-Riojas R; Gómez-Almaguer D
Blood Cells Mol Dis; 2016 May; 58():52-6. PubMed ID: 27067489
[TBL] [Abstract][Full Text] [Related]
38. Immunomodulatory strategies for relapse after haploidentical hematopoietic stem cell transplantation in hematologic malignancy patients.
Huang XJ
Best Pract Res Clin Haematol; 2011 Sep; 24(3):351-8. PubMed ID: 21925088
[TBL] [Abstract][Full Text] [Related]
39. Kinetics of recovery of dendritic cell subsets after reduced-intensity conditioning allogeneic stem cell transplantation and clinical outcome.
Talarn C; Urbano-Ispizua A; Martino R; Pérez-Simón JA; Batlle M; Herrera C; Granell M; Gaya A; Torrebadell M; Fernández-Avilés F; Aymerich M; Marín P; Sierra J; Montserrat E
Haematologica; 2007 Dec; 92(12):1655-63. PubMed ID: 18055989
[TBL] [Abstract][Full Text] [Related]
40. HLA Mismatch Is Associated with Worse Outcomes after Unrelated Donor Reduced-Intensity Conditioning Hematopoietic Cell Transplantation: An Analysis from the Center for International Blood and Marrow Transplant Research.
Verneris MR; Lee SJ; Ahn KW; Wang HL; Battiwalla M; Inamoto Y; Fernandez-Vina MA; Gajewski J; Pidala J; Munker R; Aljurf M; Saber W; Spellman S; Koreth J
Biol Blood Marrow Transplant; 2015 Oct; 21(10):1783-9. PubMed ID: 26055300
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
